Natixis Advisors LLC Has $99.89 Million Position in Elevance Health, Inc. (NYSE:ELV)

Natixis Advisors LLC grew its holdings in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 8.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 192,096 shares of the company's stock after buying an additional 14,502 shares during the quarter. Natixis Advisors LLC owned 0.08% of Elevance Health worth $99,890,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Iridian Asset Management LLC CT lifted its stake in Elevance Health by 10.7% in the third quarter. Iridian Asset Management LLC CT now owns 39,154 shares of the company's stock valued at $20,360,000 after buying an additional 3,786 shares during the last quarter. International Assets Investment Management LLC lifted its stake in Elevance Health by 85,533.1% in the third quarter. International Assets Investment Management LLC now owns 532,638 shares of the company's stock valued at $276,972,000 after buying an additional 532,016 shares during the last quarter. abrdn plc lifted its stake in Elevance Health by 32.2% in the third quarter. abrdn plc now owns 360,134 shares of the company's stock valued at $186,540,000 after buying an additional 87,717 shares during the last quarter. AMI Investment Management Inc. bought a new stake in Elevance Health in the third quarter valued at $1,294,000. Finally, Mizuho Securities USA LLC lifted its stake in Elevance Health by 185.4% in the third quarter. Mizuho Securities USA LLC now owns 51,153 shares of the company's stock valued at $26,600,000 after buying an additional 33,231 shares during the last quarter. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Elevance Health Stock Down 1.6 %

Shares of ELV traded down $6.35 during trading hours on Friday, reaching $400.69. The company's stock had a trading volume of 2,616,673 shares, compared to its average volume of 2,071,922. The firm has a market cap of $92.93 billion, a price-to-earnings ratio of 14.61, a P/E/G ratio of 1.19 and a beta of 0.85. The company has a 50 day moving average of $475.29 and a two-hundred day moving average of $513.52. Elevance Health, Inc. has a 1-year low of $397.98 and a 1-year high of $567.26. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.56.

Elevance Health (NYSE:ELV - Get Free Report) last announced its quarterly earnings results on Thursday, October 17th. The company reported $8.37 EPS for the quarter, missing the consensus estimate of $9.66 by ($1.29). The firm had revenue of $44.72 billion during the quarter, compared to the consensus estimate of $43.47 billion. Elevance Health had a net margin of 3.68% and a return on equity of 19.56%. The company's quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $8.99 EPS. As a group, research analysts predict that Elevance Health, Inc. will post 32.96 EPS for the current fiscal year.

Elevance Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 20th. Investors of record on Thursday, December 5th will be paid a $1.63 dividend. The ex-dividend date of this dividend is Thursday, December 5th. This represents a $6.52 annualized dividend and a dividend yield of 1.63%. Elevance Health's payout ratio is 23.77%.

Insider Activity at Elevance Health

In related news, EVP Charles Morgan Kendrick, Jr. sold 7,417 shares of the company's stock in a transaction on Friday, October 18th. The stock was sold at an average price of $432.14, for a total value of $3,205,182.38. Following the completion of the transaction, the executive vice president now directly owns 8,423 shares in the company, valued at approximately $3,639,915.22. This represents a 46.82 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.35% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on ELV shares. TD Cowen lowered their price target on Elevance Health from $589.00 to $484.00 and set a "buy" rating on the stock in a report on Monday, October 21st. Wells Fargo & Company lowered their price target on Elevance Health from $593.00 to $495.00 and set an "overweight" rating on the stock in a report on Monday, November 4th. Royal Bank of Canada lowered their price target on Elevance Health from $585.00 to $478.00 and set an "outperform" rating on the stock in a report on Friday, October 18th. Raymond James set a $485.00 target price on Elevance Health in a report on Friday, October 18th. Finally, Morgan Stanley dropped their price target on shares of Elevance Health from $643.00 to $551.00 and set an "overweight" rating on the stock in a research report on Wednesday, October 23rd. One analyst has rated the stock with a sell rating, two have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Elevance Health currently has an average rating of "Moderate Buy" and a consensus target price of $539.20.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.